RecruitingPhase 2NCT05868265
A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract
Studying Upper tract urothelial carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Scot Niglio, MD, MSMemorial Sloan Kettering Cancer Center
- Intervention
- Enfortumab Vedotin(drug)
- Enrollment
- 24 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2027
Study locations (8)
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
- Memorial Sloan Kettering Suffolk - Commack (Limited protocol activities), Commack, New York, United States
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
- University of Rochester Medical Center (Data Collection Only), Rochester, New York, United States
- Memorial Sloan Kettering Nassau (Limited protocol activities), Uniondale, New York, United States
Collaborators
Astellas Pharma US, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05868265 on ClinicalTrials.govOther trials for Upper tract urothelial carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07452432Korean Prospective Upper Tract Urothelial Carcinoma CohortSamsung Medical Center
- RECRUITINGNANCT07321210Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma (T-LND UTUC): A Randomized Clinical TrialTianjin Medical University Second Hospital
- RECRUITINGPHASE2NCT07265947Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial CarcinomaTyra Biosciences, Inc
- RECRUITINGPHASE2NCT07225374Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUCSamsung Medical Center
- ACTIVE NOT RECRUITINGPHASE2NCT07492225Neoadjuvant Chemotherapy Before Surgery vs Surgery Alone for UTUC: A Randomized TrialChanghai Hospital
- RECRUITINGPHASE2NCT06356155Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial CancerUniversity of Michigan Rogel Cancer Center
- RECRUITINGPHASE2NCT07126119Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUCTianjin Medical University Second Hospital
- RECRUITINGPHASE1NCT06848868Ambulatory Flexible URS for UTUC SurveillanceChinese University of Hong Kong